There is substantial interest in overexpression and enhancement of KCC2 transport activity as a novel therapeutic strategy to improve synaptic GABAergic inhibition in neurologic disorders (Kahle et al., 2008; Gagnon et al., 2013; Moore et al., 2018; Magloire et al., 2019). Here, SLC12A5 is linked to nervous system disorder.